Amgen Inc - Company Profile
Powered by
All the data and insights you need on Amgen Inc in one report.
- Save hours of research time and resources with
our up-to-date Amgen Inc Strategy Report
- Understand Amgen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreAmgen Inc (Amgen) is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines for the treatment of cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders and nephrology conditions. The company analyzes the difficulties of disease and understands the fundamentals of human biology to develop products harnessing advanced human genetics. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, the Americas and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
Amgen Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Innovative Human Therapeutics: | Aranesp |
Oncology/Hematology | Enbrel |
Cardiovascular Disease | Epogen |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Corporate Changes/Expansions | In February, the company launched its biomanufacturing site in Central Ohio. |
2023 | Others | In December, the company received the US FDA priority review for its biologics license application for tarlatamab to treat advanced small-cell lung cancer. |
2023 | Contracts/Agreements | In November, the company announced a collaboration with PostEra to leverage PostEra's Proton and the company's drug discovery expertise to advance up to 5 small molecule programs. |
Competitor Comparison
Key Parameters | Amgen Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
City | Thousand Oaks | Basel | Kenilworth | New York | North Chicago |
State/Province | California | - | New Jersey | New York | Illinois |
No. of Employees | 26,700 | 103,605 | 72,000 | 88,000 | 50,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
![Image for loader](https://assets.globaldata.com/gdcom/assets/img/ajax-loadernew.gif)
Net Income Growth
![Image for loader](https://assets.globaldata.com/gdcom/assets/img/ajax-loadernew.gif)
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Robert A. Bradway | Chairman; Chief Executive Officer | Executive Board | 2013 | 61 |
Peter H. Griffith | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 65 |
Mike Zahigian | Senior Vice President; Chief Information Officer | Senior Management | - | - |
David M. Reese, M.D | Executive Vice President; Chief Technology Officer | Senior Management | 2023 | 61 |
Nancy A. Grygiel | Chief Compliance Officer; Senior Vice President - Worldwide Compliance and Business Ethics | Senior Management | 2020 | 56 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward